ArticleMediators of inflammation2025
Targeting Kynureninase Attenuates Radiation-Induced Intestinal Injury via MAPK Signaling Suppression.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence Based on Sleep Disorder Exacerbating Postoperative Pain via Kynureninase.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kynureninase (KYNU), a key enzyme in the tryptophan-kynurenine metabolic pathway, has been increasingly recognized for its role in immune regulation and inflammation. However, its involvement in radiation-induced intestinal injury (RIII) has not been fully elucidated. In this study, we identified a significant upregulation of KYNU expression in the colonic tissues of mice with RIII using transcriptomic analysis and experimental validation. Functional assays demonstrated that KYNU knockdown in NCM460 human intestinal epithelial cells attenuated radiation-induced apoptosis and oxidative stress, while promoting cell proliferation. Mechanistically, RNA sequencing (RNA-seq) and pathway enrichment analyses revealed that KYNU regulates the mitogen-activated protein kinase (MAPK) signaling pathway, as KYNU silencing reduced the phosphorylation levels of key MAPK proteins (extracellular signal-regulated kinase [ERK], c-Jun N-terminal kinase [JNK], and p38) following irradiation. Importantly, pharmacological inhibition of KYNU using carbidopa (CBP) significantly mitigated radiation-induced epithelial injury in vitro. In the RIII mouse model, CBP administration (prevention and treatment) increased the number of crypts, improved intestinal epithelial structure, and maintained the integrity of the intestinal barrier. These findings demonstrate, that KYNU plays a critical role in the pathogenesis of RIII and that its inhibition confers protection against intestinal damage by suppressing MAPK-mediated inflammatory responses. Targeting KYNU may thus offer a promising therapeutic strategy for the prevention and treatment of RIII.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.